The analytical review of pharmaceutical market of the modern hepatoprotective drugs

  • A. V. Glushchenko National University of Pharmacy, Kharkiv
  • V. A. Georgiyants National University of Pharmacy, Kharkiv
  • Y. G. Valigura National University of Pharmacy, Kharkiv
Keywords: hepatoprotective drugs, analysis of market, hepatobiliar system

Abstract

Diseases of liver and bile passages are wide-spread pathology that has important place in the structure of morbidity and mortality of population. Therefore the therapy of diseases of the hepatobiliar system is one of the most actual problems of modern medicine.

Marketing research of the modern hepatoprotective drugs which were registered in Ukraine has been carried out using information resources by system-analytical method. The marketing analysis has been carried out by follow characteristics: country-producer, companies-producer and pharmacological group.

It has been established, that 65.15% of foreign pharmaceutical manufactures are leaders among the manufactures of this group of preparations, the part of Ukrainian preparations is 34.85%. The biggest part of all hepatoprotective drugs are the herbal hepatoprotective drugs (68.2%). 68.89% of preparations among them have been produced by foreign manufactures, and 31.11% by home manufactures.

The structure analysis of pharmaceutical market of hepatoprotective drugs has been motivated that creation of new Ukrainian phytopreparations for preventive maintenance and treatments of diseases of the hepatobiliar system are advisable.

References

1. Ivashkin V.T. Diseases of the liver and bile ducts: Hands. for doctors - M .: Published. House "M-Vesti", 2005. - 536 p.
2. Ilchenko AA Illness of the gallbladder and biliary tract. - M .: Anacharsis, 2006. - 448 p.
3. Dubosarskaya Yu. A. Diagnostics and treatment of diseases of the hepatobiliary system in the practice of a gynecologist // Med. aspects of women's health. - 2008. - No. 7-8 (17).
4. Zbrovsky A. B., Tyurenkov I. N., Belousov Yu.B. Adverse adverse effects of drugs. - M .: LLC "Medical information agency", 2008. - 656 p.
5. Kushnir I. E. Medicinal lesions of the liver // The art of treatment. - 2006. - No. 8 (34). - P. 43-47.
6. Polunina T. E., Maev I. V. Medicinal lesions of the liver // Gastroenterology. - 2011. - No. 2. - P. 54.
7. Kaplowitz N. Drug-Induced Liver Injury // Clin. Infect Dis - 2004 - V. 38, N 2. - P. S44-S48.
8. Chang C. Y., Schiano T. D. // Aliment. Pharmacol Ther - 2007. - V 25, N 10. - P. 1135-1151.
9. Chernov Yu. N. Buzlama AV, Dronova Yu. M. Polyphenolic compounds: structure, properties and applied aspects of application // Pharmamatka. - 2004. - No. 8. - P. 43-48.
10. Gromova OA, Troshin I. Yu., Jurgel I. S., and others. Mechanisms of action and clinical efficacy of combined hepatoprotective drug Prohepar // Difficult patient. - 2009. - No. 12. - P. 78-82.
11. Normative-policy documents of the Ministry of Health of Ukraine [Electronic resource]. - Mode of access: http://drlz.riev.ua/
12. Compendium 2014 [Electronic resource]. - Access mode: http://compendium.com.ua/
Published
2019-02-12
How to Cite
Glushchenko, A. V., Georgiyants, V. A., & Valigura, Y. G. (2019). The analytical review of pharmaceutical market of the modern hepatoprotective drugs. Farmatsevtychnyi Zhurnal, (4), 17-23. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/343
Section
Management of pharmacy